Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Background: Activating mutations in KRAS are prevalent in lung cancer and have been causally linked to the oncogenic process. However, therapies targeted to oncogenic RAS have been ineffective to date and identification of KRAS targets that impinge on the oncogenic phenotype is warranted. Based on published studies showing that mitotic kinases Aurora A (AURKA) and B (AURKB) cooperate with oncogenic RAS to promote malignant transformation and that AURKA phosphorylates RAS effector pathway components, the aim of this study was to investigate whether AURKA and AURKB are KRAS targets in lung cancer and whether targeting these kinases might be therapeutically beneficial. Methods: In order to determine whether oncogenic KRAS induces Aurora kinase expression, we used qPCR and western blotting in three different lung cell-based models of gain- or loss-of-function of KRAS. In order to determine the functional role of these kinases in KRAS-induced transformation, we generated KRAS-positive A549 and H358 cells with stable and inducible shRNA-mediated knockdown of AURKA or AURKB and evaluated transformation in vitro and tumor growth in vivo. In order to validate AURKA and/or AURKB as therapeutically relevant KRAS targets in lung cancer, we treated A549 and H358 cells, as well as two different lung cell based models of gain-of-function of KRAS with a dual Aurora kinase inhibitor and performed functional in vitro assays. Results: We determined that KRAS positively regulates AURKA and AURKB expression. Furthermore, in KRAS-positive H358 and A549 cell lines, inducible knockdown of AURKA or AURKB, as well as treatment with a dual AURKA/AURKB inhibitor, decreased growth, viability, proliferation, transformation, and induced apoptosis in vitro. In addition, inducible shRNA-mediated knockdown of AURKA in A549 cells decreased tumor growth in vivo. More importantly, dual pharmacological inhibiton of AURKA and AURKB reduced growth, viability, transformation, and induced apoptosis in vitro in an oncogenic KRAS-dependent manner, indicating that Aurora kinase inhibition therapy can specifically target KRAS-transformed cells. Conclusions: Our results support our hypothesis that Aurora kinases are important KRAS targets in lung cancer and suggest Aurora kinase inhibition as a novel approach for KRAS-induced lung cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On one hand, aberrant activation of KRAS and downstream MAPK/ERK signaling promotes AURKA overexpression [129–131].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 1×
“In addition, hypoxia is known to select cells that have lost their apoptotic potential [66], so it is also likely that an initial apoptotic response to AURKA inhibition might have occurred, leading to expansion of apoptotic resistant cells and failure to detect apoptotic cells at the endpoint.”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 2×
“Considering that targeting traditional KRAS effectors has so far had limited success [1, 4], the identification of novel KRAS targets that impinge on the oncogenic phenotype is warranted in order to increase the possibilities of combinatorial therapy design and achieve therapeutic efficacy.”
BackgroundRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Targeting KRAS downstream effectors has also been challenging, as KRAS regulates a multitude of effectors that contribute to the oncogenic phenotype [2, 3].”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276 · cited 2×
“In addition, both kinases have been implicated in promoting oncogenesis [20–25].”
BackgroundResultHarrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“Considering that targeting traditional KRAS effectors has so far had limited success [1, 4], the identification of novel KRAS targets that impinge on the oncogenic phenotype is warranted in order to increase the possibilities of combinatorial therapy design and achieve therapeutic efficacy.”
BackgroundEngelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
Structural Basis of Aurora-A Activation by TPX2 at the Mitotic Spindle
Bayliss, R., Sardon, T., Vernos, I., & Conti, E. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00392-7 · Cited by 636 · cited 1×
“for AURKA activity [44, 45].”
Roles of Aurora Kinases in Mitosis and Tumorigenesis
Fu, J., Bian, M., Jiang, Q., & Zhang, C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0208 · Cited by 614 · cited 2×
“This is consistent with the fact that AURKA and AURKB are master regulators of mitosis [10, 11], and that Aurora kinase inhibition is known to promote cell cycle arrest and apoptosis [14, 15].”
BackgroundResult
Cited by
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy
Yan, M., Wang, C., He, B., Yang, M., Tong, M., Long, Z., Liu, B., Peng, F., Xu, L., Zhang, Y., et al. (2016) · Medicinal Research Reviews · doi:10.1002/med.21399 · Cited by 293
Wang-Bishop, L., Chen, Z., Gomaa, A. R., Lockhart, A. C., Salaria, S. N., Wang, J., Lewis, K. B., Ecsedy, J., Washington, K. M., Beauchamp, R. D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.030 · Cited by 95
Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer
Naso, F. D., Boi, D., Ascanelli, C., Pamfil, G., Lindon, C., Paiardini, A., & Guarguaglini, G. (2021) · Oncogene · doi:10.1038/s41388-021-01766-w · Cited by 74
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
“283,284 In these cell lines, the knockdown of AURKA or AURKA/AURKB inhibition resulted in antitumor activity.”
Metadata
- Authors
- dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S.
- Affiliations
- Universidade de São Paulo (BR)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Levantini, Elena
- Venue
- Molecular Cancer
- Published
- 2016-02-03
- Volume
- 15
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC4739397
- OpenAlex
- W2256178229
- Cited by
- 64
- References
- 69
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-03-09)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2010/52685-9, 2012/13774-1, 2011/06709-6, 2011/15037-1)
- Flight Attendant Medical Research Institute (YCSA 072165, YCSA 052409, CIA 103063)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (166803/2013-8)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Aurora kinases, AURKA, Aurora B kinase, KRAS, lung cancer, oncogenic Ras, malignant transformation, mitotic kinases, shRNA knockdown, apoptosis, tumor growth, KRAS-targeted therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Lung Neoplasms, Male, Mice, Inbred BALB C, Mice, Nude, Phenotype, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Gene Knockdown Techniques, Molecular Targeted Therapy, Aurora Kinase A, Aurora Kinase B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. https://app.cochat.ai/papers/10.1186/s12943-016-0494-6
- The paper
- dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016). Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. Molecular Cancer. https://doi.org/10.1186/s12943-016-0494-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.